Log in

CVE:HEMHemostemix Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
C$0.01
MA: C$0.01
C$0.02
52-Week Range N/A
Volume216,000 shs
Average Volume1.22 million shs
Market CapitalizationC$9.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-3409207

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC($0.01) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$9.07 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HEM News and Ratings via Email

Sign-up to receive the latest news and ratings for HEM and its competitors with MarketBeat's FREE daily newsletter.

Hemostemix (CVE:HEM) Frequently Asked Questions

Has Hemostemix been receiving favorable news coverage?

News articles about HEM stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Hemostemix earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Hemostemix.

Who are some of Hemostemix's key competitors?

What other stocks do shareholders of Hemostemix own?

Who are Hemostemix's key executives?

Hemostemix's management team includes the following people:
  • Mr. Kyle Makofka, Chief Exec. Officer
  • Ms. Kristin Gulka CPA, CA, Chief Financial Officer
  • Ms. Eilat Bain, Director of Operations
  • Dr. Alan J. Jacobs, Chief Medical Consultant

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Hemostemix?

Hemostemix has a market capitalization of C$0.00.

What is Hemostemix's official website?

The official website for Hemostemix is www.hemostemix.com.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.